The Cancer Today editorial staff selects some of the most impactful reporting and essays of 2022.

by Cancer Today Staff

The editors share some of the top stories reported in Cancer Today in the past year.

Author Tara Rolle shares the challenge of staying fully present as a parent during cancer treatment and in the years that followed.

by Tara Rolle

A second KRAS inhibitor is approved for lung cancer, and a BTK inhibitor challenges standard of care for relapsed or refractory CLL.

by Marci A. Landsmann

The new AKT inhibitor doubled progression-free survival when added to treatment with Faslodex.

by Eric Fitzsimmons

Study finds pausing endocrine therapy is safe for early-stage breast cancer patients eager to expand their families.

by Thomas Celona

Black breast cancer patients had worse outcomes in a recent study, even when cancer features aligned with white patients.

by Eric Fitzsimmons

Medical marijuana used as a substitute for opioids, and chemo and endocrine therapy together increase cancer-related cognitive impairment.

by Kevin McLaughlin

AACR patient advocate forum explores how new clinical trial designs are accelerating drug testing.

by Thomas Celona

Oncologists report that prior authorization process interrupts cancer care, and plant-based diet is associated with lower colorectal cancer risk in men but not women.

by Eric Fitzsimmons